Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Jenner Institute, in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI), is set to begin a new clinical trial to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers.

BCG Challenge Study of a Novel TB Vaccine

TB is a disease caused by the bacterium Mycobacterium tuberculosis and in 2023 was the leading cause of death from an infectious disease globally. The only current licensed vaccine against TB is Bacillus Calmette-Guérin (BCG), which has remained unchanged for over a century. BCG is a weakened form of Mycobacterium bovis, which is very similar to Mycobacterium tuberculosis and is normally given as an injection in the skin at birth in areas with endemic TB. Although BCG is safe to give to infants, it does not provide life-long protection and drugs against TB are not enough to stop the financial and social burden of TB. An effective vaccine is urgently needed to reduce the spread of TB, prevent progression to active disease, and save lives.

The Jenner Institute is developing a pioneering human challenge model to test new TB vaccines. A challenge model is used to test if new vaccines work, before larger field (efficacy) studies. These models have been used to test other vaccines such as malaria, where volunteers are purposefully given malaria after the trial vaccine to see if the vaccine works.

Professor Helen McShane, Professor of Vaccinology at NDM's Jenner Institute, said: ‘The only vaccine we currently have against TB is the BCG, which unfortunately is not very effective against lung TB. We are looking at ways to deliver vaccine to the cells that will first to encounter TB bacteria, and this trial should give us important information about how our lungs respond to the early stages of infection. It will also be vitally important in the development of inhaled vaccines, which could be a much more effective way of protecting against many respiratory illnesses.’

This is the first time an aerosol BCG-challenge model will be used to test a new TB vaccine. The study is funded by the National Institute of Health’s National Institute of Allergy and Infectious Diseases as part of the IMPAc-TB consortium and is being conducted in collaboration with SCRI. The team is looking for healthy volunteers, both those who have had a BCG vaccine, and those who have never had a BCG vaccine. 

Please see the Jenner website for more information and the application questionnaire: https://www.jenner.ac.uk/volunteer/recruiting-trials/tb045  

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

New study improves early detection of life threatening infection in children across South and South East Asia

A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.